Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01930058 | Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003) | PHASE1 | COMPLETED | 9 | — | — | Oct 2, 2013 | May 5, 2014 | Oct 25, 2018 | - | — |
The mean change (log10) in HCV ribonucleic acid (RNA) from baseline to Day 7 was determined for each panel of participants.
| Arm | Type | Description |
|---|---|---|
| Panel A: HCV GT3 MK-8876 150 mg | EXPERIMENTAL | Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days. |
| Panel B: HCV GT3 MK-8876 800 mg | EXPERIMENTAL | Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days. |
| Panel E: HCV GT1a MK-8876 800 mg | EXPERIMENTAL | Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days. |
| Name | Type | Description |
|---|---|---|
| MK-8876 | DRUG | MK-8876 10 mg or 100 mg tablets taken q.d. by mouth. |
Inclusion Criteria: * is male, or female of non-childbearing potential (non-childbearing potential is defined as postmenopausal without menses for ≥1 year or after medically documented hysterectomy, oophorectomy, or tubal ligation) * agrees to use a medically acceptable method of contraception thro...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |